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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, FormosaHemostatic factors may be involved in bone health. The present preliminary study investigated
the association between plasma fibrinogen and bone mineral density (BMD) in perimenopausal
women. A significant inverse correlation between fibrinogen and BMD was observed (correla-
tion coefficient Z 0.42, p < 0.01). This correlation appeared to be more clearly observed
in the subgroup with a high level of high-sensitivity C-reactive protein than in that with a
low level of high-sensitivity C-reactive protein, and in the subgroup with a high level of diacron
reactive oxygen metabolites (an oxidative stress marker) than in that with a low level of dia-
cron reactive oxygen metabolites. Thus, fibrinogen may be a possible marker of BMD in this
population. More studies on the associations among hemostasis, inflammation, oxidative
stress, and bone metabolism are warranted in the clinical setting.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Bone loss and osteoporosis, a crucial health problem, oc-
curs with aging in women.1 This condition is caused by
multiple mechanisms that regulate osteoclastogenesis and
osteoblastogenesis.2 Although postmenopausal status has ahave no conflicts of interest
n Clinic, 2-13-5 Akasaka,
107-0052, Japan.
jp (J.-T. Chen).
5.07.023
n Medical Association. Publishedhigher plasma fibrinogen level than premenopausal status,3
a few experimental studies have recently shown a possible
contribution of hemostatic factors to bone health-
dfibrinogen may enhance bone resorption by affecting the
number and function of osteoclasts.4 Thus, clinical associ-
ations between blood fibrinogen and bone metabolism
should be confirmed using clinical laboratory examinations,
because their associations have not yet been demonstrated
in the clinical setting. The aim of this preliminary study was
to investigate the correlation between plasma fibrinogen
and bone mineral density (BMD), with special reference to
biochemical markers of inflammation and oxidative stress,
in perimenopausal women.by Elsevier Taiwan LLC. All rights reserved.
Blood fibrinogen and bone mineral density 55Methods
This study included 41 perimenopausal women who were
healthy, within mostly normal body mass index (BMI), and
free from cardiovascular, thyroid, and parathyroid dis-
eases, and severe liver or renal disorders. The study was
approved by the JT Chen Clinic Institutional Ethics Com-
mittee, and all participants provided their informed con-
sent. BMI, mean blood pressure, white blood count, serum
total cholesterol, hemoglobin A1c, high-sensitivity C-reac-
tive protein (hs-CRP), diacron reactive oxygen metabolites
(d-ROMs; an oxidative stress marker based on hydroperox-
ides),5 and plasma fibrinogen were measured with standard
methods. The lumbar L2-4 BMD was measured with dual-
energy X-ray densitometry (QDR 4500; Hologic Corp.,
Tokyo, Japan).6
Differences in the respective parameters between sub-
groups classified according to hs-CRP and d-ROMs levels
were examined using the student t test. Correlations were
examined with the Pearson correlation test and the
parameter-adjusted regression test. The hs-CRP values
were log-transformed because of their skewed distribu-
tions. A p value < 0.05 was considered significant.
Results
As shown in Table 1, a significant inverse correlation be-
tween fibrinogen and BMD was found (r Z 0.42,
p Z 0.01), whereas there were no clear correlations be-
tween the other parameters and BMD. In this population, a
significant positive correlation was seen between hs-CRP
and d-ROMs (r Z 0.47, p < 0.01). A significant positive
correlation was also observed between fibrinogen and d-Table 1 Clinical characteristics of our 41 perimenopausal
women.
Parameter Data r (p)
Age (y) 55  6 0.25 (0.12)
Body mass index (kg/m2) 21  2 0.25 (0.11)
Mean blood pressure
(mmHg)
96  12 0.07 (0.66)
Total cholesterol
(mmol/L)
5.9  0.8 0.21 (0.19)
Hemoglobin A1c (%) 5.4  0.3 0.04 (0.82)
White blood cell
count (109/L)
4.9  1.0 0.14 (0.38)
High-sensitivity CRP
(mg/dL)
0.02 (0.01e0.03) 0.10 (0.55)
d-ROMs (Carr units) 338  59 0.12 (0.47)
Fibrinogen (mg/dL) 278  45 0.42 (<0.01*)
Bone mineral density
(g/cm2)
0.93  0.15 d
Data are shown as means  standard deviations or medians
(interquartile ranges). r denotes the correlation coefficient of
each parameter with bone mineral density (by the Pearson
correlation test).
*p < 0.05.
CRP Z C-reactive protein; d-ROMs Z diacron reactive oxygen
metabolites.ROMs (r Z 0.33, p Z 0.04), as was a nonsignificant but
positive correlation between fibrinogen and hs-CRP
(r Z 0.25, p Z 0.11). The correlation between fibrinogen
and BMD remained significant after adjusting for con-
founders, such as age and BMI (adjusted correlation
coefficient Z 0.42, p Z 0.01), hs-CRP and d-ROMs
(adjusted correlation coefficient Z 0.46, p < 0.01), as
well as age, BMI, hs-CRP, and d-ROMs (adjusted correlation
coefficient Z 0.42, p Z 0.02).
When the population was divided into two groups by the
median hs-CRP level (<or  0.02 mg/dL), a more significant
inverse correlation between fibrinogen and BMD was found
in the group with high hs-CRP levels (n Z 22; mean
BMDZ 0.94  0.15 g/cm2; rZ 0.51, pZ 0.02) than in the
group with low hs-CRP levels [n Z 19; mean
BMD Z 0.92  0.15 g/cm2 (p Z 0.65 vs. the high hs-CRP
group); r Z 0.40, p Z 0.09].
Similarly, when the population was divided into two
groups by mean d-ROMs levels (<or  338 Carr units), a
more significant inverse correlation between fibrinogen and
BMD was found in the group with high d-ROMs levels
(n Z 20; mean BMD Z 0.94  0.15 g/cm2; r Z 0.54,
pZ 0.02) than in the group with low d-ROMs levels [nZ 21;
mean BMD Z 0.91  0.14 g/cm2 (p Z 0.33 vs. the high d-
ROMs group); r Z 0.40, p Z 0.07].Discussion
The present study demonstrated an inverse correlation
between blood fibrinogen and BMD levels in perimenopausal
women. Their inverse correlation was enhanced especially
in the subgroup with higher levels of CRP or d-ROMs, as
compared with those with lower levels. Even though this
study is preliminary, this is valuable as the first clinical
demonstration of the association between fibrinogen and
BMD with possible implications for menopause-related bone
health.
An animal study has reported that plasmin-deficient
mice develop osteoporosis and that this is fibrin(ogen)-
dependent, and that the derangements in the bone
remodeling unit are mechanistically tied to fibrin(ogen)-
mediated activation of osteoclasts.4 It can be hypothesized
that an increased fibrinogen level may cause bone loss by
acting directly on osteoclasts. Another clinical study has
reported an inverse correlation between the levels of
plasma fibrinogen and vitamin K (a low level of which is a
risk factor for osteoporosis), although whether it is a direct
or indirect correlation was not fully discussed, and fibrin-
ogen was discussed as an inflammatory marker in that
report.7 These studies may partly support the fibrinogen-
BMD correlation observed in the present study.4,7
Furthermore, the enhanced correlation between fibrin-
ogen and BMD in inflammatory and oxidative states may be
partly explained by earlier studies. Fibrin has been shown
to promote systemic osteoporosis in relation to inflamma-
tory states.4,7 Additionally, reactive oxygen species, lead-
ing to oxidative stress production, play a role in bone loss
by generating a more oxidized bone microenvironment.8
Osteoclasts are also shown to both be generated and acti-
vated by reactive oxygen species.9 Although inflammation
and oxidative stress often coexist (a significant positive
56 J.-T. Chen, K. Kotanicorrelation between hs-CRP and d-ROMs has been
confirmed over time10), and the interaction between both
states is complex, the mechanistic explanation for the
enhanced correlation between fibrinogen and BMD may
lead to better understanding and management of bone
health pathophysiology. This merits further investigation.
The limitations of the present study include its small
sample size and its cross-sectional design. In addition, more
data are needed, with bone metabolic markers (both for-
mation markers and resorption markers) to investigate the
effects of fibrinogen, other inflammatory cytokines (inter-
leukin-1, interleukin-6), vitamin D levels, estrogen levels,
and the BMD of proximal femur. One of the major limita-
tions is that the present study examined relatively healthy
women, and so this restricts the generalizability of the
findings. For instance, although hs-CRP is reported as a risk
marker of worse bone health,11 the association might be
difficult to observe because of the characteristics of the
present study population, who had a relatively low hs-CRP
level within a narrow range, in addition to a relatively
normal BMD level. Additional observations under several
conditions are neededdthat is, patients with various dis-
eases (e.g., overt osteoporosis, cardiometabolic disorders)
must be evaluated. Although the present study population
included some individuals with possible cardiometabolic
disorders (according to disease criteria, 2 participants with
BMI  25.0 kg/m2, 14 participants with systolic or diastolic
blood pressure  140 mmHg or 90 mmHg, 29 participants
with total cholesterol  5.7 mmol/L, and no participant
with hemoglobin A1c  6.5%), these disease conditions had
no observable effect on the correlation between fibrinogen
and BMD (data not shown). Observations in patients with
specific treatments must be conducted, because anti-
inflammatory therapy can prevent osteoporosis,12 and an
increase in BMD and reduction in fibrinogen can be seen in
postmenopausal women on tamoxifen.13 In any case, we
should acknowledge that our data cannot straightway be
applied to the field of osteoporosis; however, we expect
the results of the present preliminary study open new av-
enues for future work.
In summary, fibrinogen is a possible marker of BMD in this
population. The correlation between fibrinogen and BMD
can be enhanced under conditions of inflammation and
oxidative stress. The data provide impetus to further
investigate the associations among hemostasis, inflamma-
tion, oxidative stress, and bone metabolism in the clinical
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